

2020 Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B
(Cert # L209128)

Volume 1

Articles and Learning Objectives

Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A: Renal-Cell Carcinoma, GYN Malignancies, Oncology Practice Management

0204-9999-20-932-H01-P

Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med.* 2019; 380:1116-27.

Learning Objectives:

- Identify appropriate diagnostic, prognostic, and treatment-related tests for renal cell carcinoma.
- Discuss the dosing, administration, and toxicity profile that patients may experience with pembrolizumab/axitinib or sunitinib in metastatic renal cell carcinoma.
- Describe the efficacy of pembrolizumab/axitinib compared with sunitinib in metastatic renal cell carcinoma.

Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med.* 2018; 379:2495-505.

Learning Objectives:

- Apply the findings of the SOLO1 trial as they relate to patients with newly diagnosed ovarian cancer.
- Use patient-specific clinical data to formulate therapeutic treatment and monitoring values for patients with newly diagnosed ovarian cancer.
- Explain the adverse-effect profile of olaparib maintenance for patients with newly diagnosed ovarian cancer.

Mackler E, Segal EM, Muluneh B, et al. 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard. *J Oncol Pract.* 2019; 15:e346-e355.

Learning Objectives:

- Assess oral oncolytic workflows to ensure that safe prescribing practices, comprehensive patient education, and appropriate follow-up measures are in place to optimize medication adherence and mitigate toxicity.
- Apply a strategy for procuring oral oncolytic therapy for patients in the home setting that considers financial implications to patients and/or caregivers.
- Evaluate practice management approaches to promote interprofessional collaboration to ensure that reasonable benchmarking measures are in place for oral oncolytic management programs.

Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1B: Chronic Leukemia, Pediatric Malignancies, Hepatocellular Carcinoma, Oncology Drug Literature: Biostatistics and Study Design

0204-9999-20-933-H01-P

Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med.* 2019; 380:2225-36.

Learning Objectives:

- Interpret efficacy and safety data for a treatment regimen used in chronic lymphocytic leukemia.
- Design patient-specific treatment, supportive care, and monitoring plans for patients with chronic lymphocytic leukemia.
- Manage toxicities associated with a treatment regimen used in chronic lymphocytic leukemia.

Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization. *J Clin Oncol.* 2018; 36:2926-34.

Learning Objectives:

- Design patient-specific treatment and monitoring plans for children and young adults with T-lineage acute lymphoblastic leukemia.
- Manage toxicities associated with treatment regimens for patients with T-lineage acute lymphoblastic leukemia.
- Interpret the efficacy and safety results of the Winter et al. study comparing two methotrexate regimens.

Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019; 20:282-96.

Learning Objectives:

- Evaluate the outcomes of the REACH-2 in patients with advanced hepatocellular carcinoma.
- Assess patients with advanced hepatocellular carcinoma to determine whether they are eligible for treatment with ramucirumab.
- Design a supportive care plan for patients with advanced hepatocellular carcinoma receiving ramucirumab.

Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. *N Engl J Med.* 2017; 377:62-70.

Learning Objectives:

- Explain the differences between the types of master protocols and in what therapeutic areas these studies most commonly occur.
- Describe areas of innovation for master protocols.
- Design basket, umbrella, and platform protocols to answer oncology-related questions.

Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. *J Clin Oncol.* 2018; 36:2532-7.

Learning Objectives:

- Explain the differences between the types of master protocols and in what therapeutic areas these studies most commonly occur.
- Describe areas of innovation for master protocols.
- Design basket, umbrella, and platform protocols to answer oncology-related questions.